Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Vitiligo Clinical Trial

— BARVIT  

Official title:

Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04822584
• Other study ID #: CHUBX 2019/21
• Status: Completed
• Phase: Phase 2
• Start date: July 16, 2021
• Est. completion date: April 26, 2023

Study information

• Verified date: June 2023
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this phase 2 study is to evaluate the effect and the safety of the combination of Baricitinib in combination with phototherapy in adult participants with non-segmental progressive vitiligo.

Description:

Treatment Strategy: Multicentric, parallel double blind randomized phase 2 prospective study comparing baricitinib (4mg/day) + narrowband UVB TL01 versus placebo + narrowband UVB TL01 Follow-up of the study: patients included in this study will start Baricitinib 3 months before starting narrowband UVB TL01. Phototherapy will be performed twice a week during 6 months. Follow-up visit will be done at week 12, 24, 36 and 48.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: April 26, 2023
• Est. primary completion date: April 26, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subject: male or female aged = 18 years and = 75 years

• Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet

• Active non-segmental vitiligo is defined by:

• Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND

• Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination.

• Able to read, understand, and give documented (electronic or paper signature) informed consent

• Registered in the French Social Security

• Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization (Visit 2) and throughout the study: systemic steroids, phototherapy, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine.

• Agree to discontinue the use of the following excluded medications for at least 2 weeks prior to randomization (Visit 2) and throughout the study:

• TCS or topical immune modulators (e.g., tacrolimus or pimecrolimus)

• Topical phosphodiesterase type 4 (PDE-4) inhibitor (crisaborole)

• Topical JAK inhibitor (e.g., tofacitinib or ruxolitinib) and/or any other investigational topical treatments.

• Patient characteristics

• Are male or nonpregnant, nonbreastfeeding female patients, except:

1. Male patients must agree to use 2 forms of birth control (1 must be highly effective, see below) while engaging in sexual intercourse with female partners of childbearing potential while enrolled in the study and for at least 4 weeks following the last dose of investigational product.

2. Female patients of childbearing potential must agree to use 2 forms of birth control, when engaging in sexual intercourse with a male partner while enrolled in the study and for at least 4 weeks following the last dose of investigational product.

The following birth control methods are considered acceptable (the patient should choose 2 to be used with their male partner, and 1 must be highly effective):

• Highly effective birth control methods: oral, injectable, or implanted hormonal contraceptives (combined estrogen/progesterone or progesterone only, associated with inhibition of ovulation); intrauterine device or intrauterine system (e.g., progestin-releasing coil); or vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate).

• Effective birth control methods: condom with a spermicidal foam, gel, film, cream, or suppository; occlusive cap (diaphragm or cervical/vault caps) with a spermicidal foam, gel, film, cream, or suppository; or oral hormonal contraceptives.

3. Females of nonchildbearing potential are not required to use birth control and they are defined as:

• Women =60 years of age or women who are congenitally sterile, or

• Women =40 and <60 years of age who have had a cessation of menses for =12 months and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (=40 mIU/mL or =40 IU/L), or women who are surgically sterile (i.e., have had a hysterectomy or bilateral oophorectomy or tubal ligation).

• Signed informed consent form (ICF)

Exclusion Criteria:

• Segmental or mixed vitiligo

• Patients that are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus) that would interfere with evaluations of the effect of study medication on vitiligo

• Patients who are currently experiencing a skin infection that requires treatment, or who are currently being treated with topical or systemic antibiotics.

Note: Patients may not be rescreened until at least 4 weeks after the date of their previous screen failure and at least 2 weeks after resolution of the infection.

• Patients that have any serious concomitant illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring. (e.g., unstable chronic asthma).

• Patients that have been treated with the following therapies:

1. Monoclonal antibody (e.g., ustekinumab, omalizumab, dupilumab) for less than 5 half-lives prior to randomization.

2. Received prior treatment with any oral JAK inhibitor (e.g., tofacitinib,ruxolitinib)

3. Received any systemic corticosteroid administered within 4 weeks prior to planned randomization or are anticipated to require systemic corticosteroids during the study.

4. Have had an intra-articular corticosteroid injection within 4 weeks prior to planned randomization.

5. Have received more than 250 sessions of UV lights therapies.

• Patients that are largely or wholly incapacitated permitting little or no self-care, such as being bedridden.

• Patients that have uncontrolled arterial hypertension characterized by a repeated systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg in a seated position.

• Patients that have had any major surgery within 8 weeks prior to screening or that will require major surgery during the study that, in the opinion of the investigator, would pose an unacceptable risk to the patient.

• Patients that are immunocompromised and, in the opinion of the investigator, at an unacceptable risk for participating in the study.

• Patients that have experienced any of the following event within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.

• Patients that have a history of recurrent (= 2) VTE or are considered at high risk of VTE as deemed by the investigator.

• Patients that have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.

• Patients that have a history of lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for less than 5 years :

1. Patients with cervical carcinoma in situ that has been resected with no evidence of recurrence or metastatic disease for at least 3 years may participate in the study.

2. Patients with basal cell or squamous epithelial skin cancers that have been completely resected with no evidence of recurrence for at least 3 years may participate in the study.

• Patients that have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection, including but not limited to the following:

Note: A recent viral upper respiratory tract infection or uncomplicatedurinary tract infection should not be considered clinically serious.

1. symptomatic herpes zoster infection within 12 weeks prior to screening.

2. history of disseminated/complicated herpes zoster (e.g., multidermatomal involvement, ophthalmic zoster, CNS involvement, or post-herpetic neuralgia).

3. symptomatic herpes simplex at the time of randomization.

4. active or chronic viral infection from hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

5. household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.

6. evidence of active TB or have previously had evidence of active TB and did not receive appropriate and documented treatment.

7. clinically serious infection or received intravenous antibiotics for an infection, within the past 4 weeks of randomization.

8. any other active or recent infection within 4 weeks of randomization that, in the opinion of the investigator, would pose an unacceptable risk to the patient if participating in the study.

• Patients that have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination).

Note: Patients eligible for herpes zoster vaccine, who have not received it prior to screening will be encouraged (per local guidelines) to do so prior to randomization; vaccination must occur >4 weeks prior to randomization and start of investigational product. Patients will be excluded if they were exposed to herpes zoster vaccination within 4 weeks of planned randomization.

Investigators should review the vaccination status of their patients and follow the local guidelines for vaccination of those =18 years of age with nonlive vaccines intended to prevent infectious disease prior to entering patients into the study

• Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within the 2 years prior to screening.

• Presence of significant uncontrolled neuropsychiatric disorder, are clinically judged by the investigator to be at risk for suicide.

• Have donated more than a single unit of blood within 4 weeks prior to screening or intend to donate blood during the course of the study.

Other non inclusion criteria:

• Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures.

• Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

• Have participated within the last 30 days in a clinical study involving an investigational product. If the previous investigational product has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives (whichever is longer) should be allowed between the end of the previous treatment and the inclusion.

• Have previously been randomized in this study or any other study investigating baricitinib.

• Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

Diagnostic Assessments

• Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator, are clinically significant and indicate an unacceptable risk for the patient's participation in the study.

• Have evidence of active TB or latent TB:

1. have evidence of active TB, defined in this study as the following:

• Documented by a positive PPD test (=5 mm induration between approximately 48 and 72 hours after application, regardless of vaccination history), medical history, clinical features, and abnormal chest x-ray at screening.

• The QuantiFERON®-TB Gold test or T-SPOT®.TB test (as available and if compliant with local TB guidelines) may be used instead of the PPD test. Patients are excluded from the study if the test is not negative and there is clinical evidence of active TB.

Exception: Patients with a history of active TB who have documented evidence of appropriate treatment, have no history of re-exposure since their treatment was completed, and have a screening chest x-ray with no evidence of active TB may be enrolled if other entry criteria are met. Such patients would not be required to undergo the protocol-specific TB testing for PPD, QuantiFERON®-TB Gold test, or T-SPOT® TB test but must have a chest x-ray at screening.

Related Conditions & MeSH terms

• Vitiligo

Intervention

Drug:
• Baricitinib Oral Product
Baricitinib 4 mg/day orally for 36 weeks
• Placebo
Placebo once a day orally for 36 weeks

Locations

Country	Name	City	State
France	Service de Dermatologie - Hôpital Saint-André	Bordeaux
France	Service de dermatologie - Hôpital Henri Mondor - EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques)	Créteil
France	Centre Hospitalier Universitaire de Nice - Service de Dermatologie	Nice
France	Service de dermatologie Centre de Référence des Maladies Rares de la Peau et des muqueuses d'origine génétique - Hôpital Larrey	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Score with Vitiligo Area Scoring Index (VASI)	The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.	week 36
Secondary	Score with VASI score	Change in percentage of repigmented Surface area 12 weeks after-inclusion, by using the VASI score at week 12.; The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.	week 12
Secondary	Score with VASI score	Change in percentage of repigmented Surface area 24 weeks after-inclusion, by using the VASI score at week 24.; The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.	week 24
Secondary	Score with VASI score	Change in percentage of repigmented Surface area 48 weeks after-inclusion, by using the VASI score at week 48.; The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.	week 48
Secondary	Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score	Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 12	week 12
Secondary	Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score	Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 24	week 24
Secondary	Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score	Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 36	week 36
Secondary	Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score	Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 48	week 48
Secondary	Number of Adverse Events (AE) and serious adverse events (SAE), as well as the proportion of discontinuation due to AEs and/or SAEs	AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related, that occurs after a subject provides informed consent. Abnormal laboratory values or test results occurring after informed consent constitute AEs only if they induce clinical signs or symptoms, are considered clinically meaningful, require therapy, or require changes in the study drug.	week 36
Secondary	Evaluation of score Vitiligo European Task Force (VETF)	Variation of the score Vitiligo European Task Force (VETF) The VETF score is used to assess the severity and extent of vitiligo. The VETF assesses 3 dimensions of the disease in 5 areas (Head/neck, hands and feet, trunk, arms, legs) namely 1/ extent: percentage of vitiligo involvement estimated using the rule of nines, 2/ depigmentation severity grading (stage 0: normal pigmentation Stage 1: incomplete pigmentation , stage 2 complete depigmentation, stage 3: partial hair whitening <30% stage 4: complete hair whitening) and 3/ spreading (score O: similar limits, Score 1: progressive vitiligo; score -1: regressive vitiligo).	Week 12
Secondary	Evaluation of score Vitiligo European Task Force (VETF)	Variation of the score Vitiligo European Task Force (VETF) The VETF score is used to assess the severity and extent of vitiligo. The VETF assesses 3 dimensions of the disease in 5 areas (Head/neck, hands and feet, trunk, arms, legs) namely 1/ extent: percentage of vitiligo involvement estimated using the rule of nines, 2/ depigmentation severity grading (stage 0: normal pigmentation Stage 1: incomplete pigmentation , stage 2 complete depigmentation, stage 3: partial hair whitening <30% stage 4: complete hair whitening) and 3/ spreading (score O: similar limits, Score 1: progressive vitiligo; score -1: regressive vitiligo).	Week 24
Secondary	Evaluation of score of the Vitiligo Extent Score (VES)	Variation in percentage of the Vitiligo Extent Score (VES). The VES score is used to assess the severity and extent of vitiligo. Using the VES calculator www.vitiligo-calculator.com, investigator choose the pictures that best represent the patient's skin lesions and then the percentage of depigmented area is calculated.	Week 36
Secondary	Evaluation of score of the Vitiligo Extent Score (VES)	Variation in percentage of the Vitiligo Extent Score (VES). The VES score is used to assess the severity and extent of vitiligo. Using the VES calculator www.vitiligo-calculator.com, investigator choose the pictures that best represent the patient's skin lesions and then the percentage of depigmented area is calculated.	Week 48
Secondary	Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)	Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.	Week 12
Secondary	Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)	Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.	Week 24
Secondary	Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)	Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.	Week 36
Secondary	Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)	Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.	Week 48
Secondary	Evaluation of score of the Dermatology Life Quality Index (DLQI)	Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.	week 12
Secondary	Evaluation of score of the Dermatology Life Quality Index (DLQI)	Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.	week 24
Secondary	Evaluation of score of the Dermatology Life Quality Index (DLQI)	Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.	week 36
Secondary	Evaluation of score of the Dermatology Life Quality Index (DLQI)	Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.	week 48
Secondary	Evaluation of the score of the Skindex 29	Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.	Week 12
Secondary	Evaluation of the score of the Skindex 29	Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.	Week 24
Secondary	Evaluation of the score of the Skindex 29	Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.	Week 36
Secondary	Evaluation of the score of the Skindex 29	Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.	Week 48
Secondary	Evaluation of blood inflammatory markers using immunofluorescence on skin biopsies and ELISA multiplex.	Expression of IFN-a, TNF-a, IFN-?, IL-4, IL-5, IL-12, IL-13, IL-15, IL-17, IL-22, IL-23, IL-33 CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCL20, soluble HSP70.	day 1
Secondary	Evaluation of blood inflammatory markers using immunofluorescence on skin biopsies and ELISA multiplex.	Expression of IFN-a, TNF-a, IFN-?, IL-4, IL-5, IL-12, IL-13, IL-15, IL-17, IL-22, IL-23, IL-33 CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCL20, soluble HSP70.	week 12
Secondary	Evaluation of blood inflammatory markers using immunofluorescence on skin biopsies and ELISA multiplex.	Expression of IFN-a, TNF-a, IFN-?, IL-4, IL-5, IL-12, IL-13, IL-15, IL-17, IL-22, IL-23, IL-33 CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCL20, soluble HSP70.	week 36